A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

September 11, 2024

Study Completion Date

November 15, 2024

Conditions

Transthyretin-mediated Amyloidosis

Interventions

DRUG

Eplontersen Solution for Injection

an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg.

Trial Locations (1)

Research Site, Beijing